Document is current
Any future updates will be listed below
-
Authors
Lerchner, Tobias
Heymans, Stephane S. R. https://orcid.org/0000-0001-9477-7803
- License Information
-
More Information
Article History
First Online: 8 September 2026
Ethics
Competing interests: T.L. received personal fees outside the submitted work from Bayer and Pfizer, and receives funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, 569395831). S.S.R.H. receives personal fees for independent scientific advice for AstraZeneca, Ribocure and CSL Behring; received research support from AstraZeneca and CSL Behring; the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, Dutch Cardiovascular Alliance CVON2016 Early HFPEF 2015-10, CVON She PREDICTS grant 2017-21, CVON Arena PRIME 2017-18, and DCVA Double Dosis 2020 B005; and from IMI2 CARDIATEAM (821508); and is a member of the European Reference Network for rare, low prevalence, and complex diseases of the heart (ERN GUARD Heart).
